D
ifferentiated thyroid carcinoma (DTC), which comprises papillary (PTC) and follicular thyroid carcinoma (FTC), is a rare disease during childhood. Age-standardized incidence rates for children 0 -4 years of age are 0.4 per 100.000, and up to 1.5 per 100.000 for adolescents aged 15-19 years (1). However, DTC is the most common pediatric endocrine malignancy and its incidence is increasing (1) (2) (3) . The prognosis in children has been reported to be excellent with 15-year survival rates Ͼ 95% (3) . Due to sparse pediatric data, however, thyroid cancer care for pediatric patients is based predominantly on evidence from adult series. This year, the American Thyroid Association (ATA) published their first guidelines for children with DTC, thereby providing a thorough overview of the available literature (4) .
The initial treatment for children with DTC generally consists of a (near) total thyroidectomy with or without lymph node dissection, although for patients with minimally invasive FTC Յ 4 cm and lacking other adverse risk factors, a less aggressive treatment has recently been recommended (4, 5) . Complication rates of thyroid surgery in children have been reported to be higher than those in adults (6) . In most cases, surgery is followed by ablation therapy with radioactive iodine (131-I) to destroy residual tumor foci and to facilitate disease monitoring by follow-up scans and measurement of serum thyroglobulin (Tg). However, nowadays 131-I administration often depends on risk stratification (4, 5) . Pediatric patients with residual tumor and/or metastases are generally treated by cyclic 131-I administrations, with the activity of 131-I being a matter of discussion (7) . To decrease the risk of recurrent disease, TSH suppressive therapy with thyroid hormone has for decades been considered necessary during follow-up, but its use is currently tempered in patients showing no evidence of disease (4, 8 -10) .
Awareness regarding treatment-related morbidity is growing. However, long-term follow-up data, especially long-term data on morbidity, of children not exposed to the post-Chernobyl fallout are limited. Past studies in children Յ 18 years at diagnosis have frequently been hampered by short follow-up, small patient series, series including patients with benign conditions, or treatment regimens not representative of current practice (eg, including external beam radiotherapy) (11) (12) (13) (14) (15) . Therefore, detailed insight into relevant clinical parameters of DTC in children is necessary to improve evidence-based treatment and follow-up strategies. The objective of this nationwide study was to evaluate the presentation, complications, and long-term outcome in patients with pediatric DTC in the Netherlands.
Patients and Methods

Study design and population
In this nationwide retrospective cohort study, children Յ 18 years diagnosed with PTC or FTC between January 1970 and December 2013 and treated in the Netherlands were eligible for inclusion. The Dutch population is considered to be iodine-sufficient with virtually no exposure to the post-Chernobyl radioiodine fallout (16) . To create a national cohort with coverage as high as reasonably feasible, patients were traced using data from the Netherlands Cancer Registry (1989 -2013) and from hospital registries of the University Medical Centers (UMCs), in which patients were generally registered from 1970 onwards. Mortality data were obtained from electronic hospital patient information systems. For patients lost to follow-up, linkage with the database of the Central Bureau for Genealogy in the Netherlands was performed to identify deceased subjects. The Institutional Review Board of the University Medical Center Groningen approved the study. Informed consent was given by the patients and/or by their parents, for minors.
Data collection
Medical history, diagnosis, and treatment details were obtained from patients' medical records. Histopathological data were obtained from the original pathology reports. As the TNM Classification of Malignant Tumors was changed several times within the period covered by this study, tumor stage was (re-)classified according to the seventh edition of the TNM classification to facilitate comparison of the tumors (17) . Data regarding 131-I administrations (number and activities of 131-I, and results of scans, both therapeutic and imaging) were collected from reports of the Departments of Nuclear Medicine. To calculate the cumulative administered 131-I activity, only ablative and therapeutic 131-I administrations were taken into account. TSH values were collected from the laboratory reports. In case of missing data, medical correspondence and the general practitioner were consulted.
Study definitions
Date of diagnosis was defined as the date of histological confirmation of thyroid carcinoma. Follow-up time was calculated from the date of diagnosis until the date of the patient's last known assessment or the date of the patient's death. Age at diagnosis was classified into 3 groups: age 0 -10, 11-14 and 15-18 years. Transient and permanent hypoparathyroidism were defined by the use of calcium or vitamin D supplements for less than 6 months, and more than 6 months after thyroidectomy, respectively, or if these conditions were reported as such in the medical records. Recurrent laryngeal nerve (RLN) injury was defined as injury mentioned in Ear Nose and Throat report or, if this report was not available, in other medical records. Injury due to encasement by tumor was also defined as recurrent laryngeal nerve injury. Remission was defined as the absence of clinical, scintigraphical, or radiologic evidence of disease and undetectable serum Tg under TSH suppressive therapy for at least 1 year after the last 131-I therapy. Persistent disease was defined as the absence of remission. Recurrent disease was defined as histological, cytological, radiological, or biochemical evidence of disease after remission. Patients were classified according to risk of recurrence: low (T1-T2, N0, M0), intermediate (any T3 or N1 tumor), or high (any T4 or M1 tumor).
Statistical analysis
Groups were compared using 2 (18) . Logistic regression analyses were performed to explore the associations between TSH level and recurrent disease, and between the occurrence of surgical complications and hospital volume, time of surgery, and age group. Regarding the association between TSH and recurrent disease, TSH was entered continuously in the crude model, followed by adjustment for risk classification. The associations between surgical complications and hospital volume, time of surgery, and age group were explored in a crude model, followed by adjustment for T-stage (T1-T2 vs T3-T4) and the performance of lymph node dissection. Patients surgically treated in Ͼ 1 hospital were excluded from the analysis, as it was retrospectively unclear in which hospital the complication occurred. All tests were two-sided. A P value of Ͻ 0.05 was considered significant. IBM SPSS Statistics version 22 (IBM, Armonk, NY, USA) was used for statistical analyses.
Results
As shown in the study flowchart (Figure 1 
Baseline characteristics
Baseline characteristics are provided in Table 1 . The female: male ratio was 5.2:1. Median age at diagnosis was 15.6 (range 5.8 -18.9) years. PTC was diagnosed in 81.0% of the patients; the remaining 19.0% had FTC. At initial diagnosis, histologically confirmed cervical lymph node metastases were found in 46 (43.8%) patients and distant metastases in 14 (13.3%) patients. Of these, 11 patients had lung metastases, 1 patient with FTC had a metastasis in the seventh thoracic vertebra and 2 patients with PTC and FTC, respectively, had both lung and bone metastases. press.endocrine.org/journal/jcemPathological features and TNM stage did not differ between the 3 age groups.
Medical history
Four (3.8%) patients developed DTC as a second malignant neoplasm (SMN); 2 of them had been treated with cranial radiotherapy (Supplemental Table 2 ). One patient with a neuroblastoma had been treated with 131-I-metaiodobenzylguanidine (previously reported (19) ). The fourth patient had been treated for Langerhans cell histiocytosis. She did not receive radiotherapy. Two (1.9%) patients developed PTC after radiotherapy directed to the neck for benign conditions.
Surgical treatment
Total thyroidectomy was performed in all patients. In 65 (61.9%) patients the total thyroidectomy was performed as a single procedure. In the remaining 40 (38.1%) patients a diagnostic hemithyroidectomy was performed, followed by a completion thyroidectomy. The mean time span between both procedures was 31.5 (range 2-210) days.
Lymph node dissection was performed as part of initial therapy in 46 (43.8%) patients, of whom 40 (87.0%) had histologically proven lymph node metastases. In 10 (9.5%) patients the central compartment (level VI) was dissected; in 36 (34.4%) patients a lateral lymph node dissection was performed, including other levels (II-V) on one or both sides of the neck (Table 1 ). In 6 patients not initially treated with a lymph node dissection, positive lymph nodes were found during histopathological examination. Central compartment dissection alone was performed more frequently in children aged 0 -10 years, while in older children lateral levels were more often included in the lymph node dissection (P ϭ .045, Table 1 ).
Throughout the entire study period, patients were surgically treated in 39 hospitals, including 9 UMCs and 30 general hospitals. During this period, in our cohort, the median number of surgical procedures (hemi-or total thy- roidectomy, or lymph node dissection, when performed at different dates) per hospital was 2 (range 1-30). Over the past decade, 50 patients were treated in 16 different hospitals, including 9 UMCs and 7 general hospitals.
Surgical complications
As shown in Table 2 , postoperative transient and permanent hypoparathyroidism were observed in 16 (15.2%) and 25 (23.8%) patients, respectively. Both transient and permanent hypoparathyroidism occurred more often in patients who underwent a lymph node dissection. Unilateral RLN injury occurred in 12 (11.4%) patients. Bilateral RLN injury occurred only in a 15-year-old patient with extended disease who was treated with a total thyroidectomy, a central compartment dissection and a bilateral modified lymph node dissection. The right RLN was encased by the tumor and was removed as part of the surgical procedure. RLN injury occurred more often in patients with tumors staged T3-T4 compared to stage T1-T2 (P Ͻ .001), and in patients with lymph node involvement (P Ͻ .001). The frequency of surgical complications did not differ between initial surgery performed before or during the last decade, either in a crude model or after adjustment for T-stage and performance of lymph node dissection (OR 0.96, 95% CI 0.42 to 2.17, P ϭ .912 and OR 0.94, 95% CI 0.32 to 2.72, P ϭ .904, respectively). Finally, age group was not related to the occurrence of surgical complications, either in a crude or adjusted model (P ϭ .550 and P ϭ .189, respectively).
131-I administrations and TSH suppressive therapy
Data regarding 131-I administrations are provided in Table 3 . One hundred and two (97.1%) patients were treated with 131-I, with a median cumulative activity administered during initial treatment and follow-up of 5.66 (range 0.74 -35.15) GBq. The median number of 131-I administrations was 1 (range 1-6). Ninety-four (89.5%) patients underwent 131-I ablation therapy within 6 months after initial surgical treatment. By doctor's choice, 3 patients did not receive 131-I ablation therapy. Higher tumor stage (T3-T4), lymph node involvement, and distant metastases were independently associated with a higher administered cumulative 131-I activity (P Ͻ .001) and with an increase in the number of 131-I administrations (P Ͻ .001). The cumulative 131-I activity and the number of 131-I administrations during initial treatment and follow-up did not differ between age groups at diagnosis (P ϭ .227 and P ϭ .225, respectively, data not shown). Pulmonary fibrosis was not encountered in the medical charts. No patients were treated with external beam radiotherapy, chemotherapy or tyrosine kinase inhibitors for DTC. TSH values of 104 (99.0%) patients were available for analysis. Median TSH level during follow-up was 0.17 (range 0.01-4.74) mU/L. TSH was suppressed below 0.10 mU/L during the entire follow-up in 36 (34.6%) patients. The TSH level was not associated with recurrent disease, either in a crude model (OR 1.98, 95% CI 0.80 to 4.86, P ϭ .140), or after adjustment for risk classification (OR 2.00, 95% CI 0.78 to 5.17, P ϭ .152).
Outcome
At last known follow-up, 9 (8.6%) patients had persistent disease, 6 of whom were classified as such based on a detectable Tg level. Eight (7.6%) patients experienced a recurrence (Table 4) . Recurrence free survival (RFS) from initial treatment to first recurrence ranged from 3.9 to 22.7 years. Three out of 8 patients relapsed within 5 years after initial treatment. Of the 11 (10.5%) patients who had not been treated with 131-I within 6 months after total thyroidectomy, 2 developed a recurrence (P ϭ .197, data not shown). As shown in Table 5 , T3-T4 stage, lymph node involvement, and distant metastases stage were associated with persistent disease (P ϭ .040, P ϭ .010 and P ϭ .020, respectively). No associations were found between initial TNM stage and recurrences. The 3 patients who initially presented with bone metastases became free of disease after administration of 13.7, 11.8 and 14.8 GBq 131-I, and remained in remission after a follow-up of 2.9, 5.1 and 13.2 years, respectively. Outcome did not differ between patients with PTC and FTC, or between the 3 age groups (P ϭ .411 and P ϭ .789, respectively, data not shown). Outcome could not be assessed for 2 patients because of follow-up Ͻ 1 year. For another patient, information to evaluate outcome was not available. Median follow-up in patients with recurrent disease was 24.7 (10.7-41.5) years, significantly longer than in patients who remained in remission (11.4 (1.3-44.7) years) and in patients with persistent disease (5.5 (1.7-36.1) years) (P ϭ .030, data not shown).
Data regarding SMNs after pediatric DTC are provided in Supplemental Table 3 .
Discussion
This nationwide study of pediatric patients with well-differentiated thyroid cancer in the Netherlands confirms an excellent overall survival. All patients underwent total thyroidectomy with nodal dissection in 43.8%, followed in most patients by high-dose 131-I ablation therapy. Over a 43-year period, 105 patients were surgically treated in 39 hospitals. In 32.4% of them lifelong postoperative complications (permanent hypoparathyroidism and/or RLN injury) were present. A significant number of patients had persistent disease or experienced a recurrence. Despite small patient numbers, our cohort is one of the largest to be described for this rare disease in children. It gives insight into relevant clinical parameters that can be used to improve evidence-based treatment and follow-up strategies.
In our opinion, the incidence of hypoparathyroidism, using strict definitions in our cohort, seems to be relatively high compared to comparable cohorts of pediatric pa- tients treated for DTC (transient and permanent hypoparathyroidism in 15.2% and 23.8%, respectively, previously described in 7.4 -32.7% and 0%-32%, respectively) (12, 20 -23) . In adults, these complications were less frequently encountered (6.2-14.2% and 0 -4.0%, respectively) (24, 25) . The occurrence of RLN injury in our cohort (12.4%) was comparable with other pediatric cohorts (0%-40%), as well as with reported adult data (0 -38.4%) (14, 21, 26, 27 ). However, it should be considered that definitions of surgical complications are heterogeneous. Complication rates therefore vary widely in the literature. Total thyroidectomy, which is recommended for the vast majority of pediatric patients with DTC, is associated with a higher complication risk than partial thyroidectomy, particularly when combined with lymph node dissection (4 -6, 13). Another major factor that could have contributed to our complication rates might be the high number of centers where surgery was performed on this low volume high-risk patient group. Due to the low numbers of surgical treatments per hospital in our cohort we were not able to analyze differences in the occurrence of surgical complications between high-and low-volume centers. However, it has been shown that complications of thyroid surgery in pediatric patients are reduced when surgery is performed by high-volume surgeons (6) . High-volume surgery may also be associated with fewer incomplete resections. Therefore the need for further centralization of care for pediatric patients with DTC is essential, as has been recommended by the ATA (4).
The cumulative therapeutic 131-I activity during initial treatment and follow-up in our cohort was relatively high. Given the good survival rate, it can be questioned whether children could just as well be treated with lower therapeutic activities, as suggested by recent guidelines (4, 5).
The dosage of 131-I is of importance, given that pulmonary fibrosis was observed as a side effect in 7.2% of patients with lung metastases in a high-risk Chernobyl-related pediatric cohort (28) . In our cohort we did not observe pulmonary fibrosis after a similar follow-up period. As the presence of pulmonary fibrosis was assessed from medical records in our study, we may have missed subclinical cases. Nevertheless, it is our opinion that the administration of 131-I should be considered very carefully in pediatric patients to prevent possible early and late adverse effects (29, 30) . This is especially the case in children with low-risk DTC as no benefit of 131-I ablation therapy has been shown in adults with low-risk disease (31) . High 131-I activities should be reserved for children with metastatic disease, as advocated earlier by Verburg et al (7) .
In about one-third of the patients in our cohort TSH was suppressed during the entire follow-up. To the best of our knowledge, our study is the first to report that TSH level is not associated with recurrent disease in children with DTC. This finding upholds the first ATA guidelines for pediatric patients with DTC, which recommend tempering TSH suppression in children showing no evidence of disease (4) . However, this should be interpreted carefully as our study probably has a lack of power.
The prevalence of cervical lymph node metastases at initial diagnosis in our cohort (43.8%) is in the lower range of prevalences as reported in other pediatric series (39%-90%) (15, 21, 22, (32) (33) (34) . The prevalence of distant metastases in our study is comparable to that from other pediatric cohorts (32, 33) .
Persistent disease was more often found in patients with higher T stage, cervical lymph node involvement and distant metastases at diagnosis. One-third of the patients with persistent disease had lung metastases at last known We report a recurrence rate of 7.6%, which is low compared with a study involving comparable treatment and follow-up (18.8%) (33) . Our study definitions of recurrent disease may have contributed to the low recurrence rate, as we did not interpret disease activity within 1 year after initial treatment as recurrent disease. In contrast to some other studies, in our cohort recurrences were not associated with initial TNM stage and did not differ between age groups (14, 33, 35) . RFS ranged from 3.9 -22.7 years. This favors lifelong follow-up of children. Patients with recurrent disease were significantly longer in follow-up compared to patients in remission and with persistent disease. This prolonged follow-up might be explained by the wish of physicians to follow patients with recurrent disease for a longer time than patients who remain in remission.
Possible differences in presentation of sporadic DTC compared to radiation-induced DTC could not be detected, as the number of patients with SMN in our cohort was low and the median follow-up was relatively short to develop a SMN.
Limitations of this study are related to its retrospective design. As patients were treated in many hospitals over more than 40 years, complete information from medical records could not always be retrieved. Furthermore, preoperative staging and patient management were not similar in all hospitals and have evolved over time. In addition, the association between lymph node dissection and occurrence of surgical complications should be interpreted carefully as the number of procedures per hospital was small and information on the selection criteria for the extent of surgery was often lacking. However, over the last decades the general consensus on treatment for pediatric DTC has in the Netherlands remained roughly unchanged. Finally, various TSH assays have been used. However, we expect limited influence of the assay differences on the results, as the lower limits of the reference ranges remained more or less stable.
In conclusion, the life expectancy for children with DTC is excellent. However, many patients experience adverse effects from thyroid surgery, resulting in lifelong complications in 32.4%. Centralization of care for pediatric patients with DTC is crucial to reduce treatmentrelated damage in this young patient group. In the near future, treatment for pediatric patients with DTC will be further centralized in one or two hospitals in The Netherlands. Furthermore, the administration of 131-I should be weighed very carefully to prevent early and late adverse events. Further studies are needed to evaluate long-term sequels. International collaboration using homogeneous definitions can accelerate evaluation and improvement of treatment for children with DTC. 
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